Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis

Completed · Phase 3

Conditions studied: Eosinophilic Esophagitis

In brief

This study is an open-label study where all subjects will receive active drug, reslizumab. Subjects are able to enter this trial only through completion of study Res-05-0002 (NCT00538434). The goal of the study is to show longer term safety and efficacy in pediatric subjects who have eosinophilic esophagitis.

Key facts

Study ID
NCT00635089
Run by
Ception Therapeutics
People needed
190
Starts
2008-07-01
Expected to finish
2012-01-01
Last updated by the study team
2017-03-23

Who can join

Age: 5 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.